Table 1 Summary characteristics of the study cohort
From: Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection
Patients with pharyngeal swab samples | ||||
Clinical indexes | Healthy controls (N=29, n=39) | Patient (N=96, n=174) | ||
Mild (N=19, n=31) | Moderate (N=51, n=73) | Severe (N=26, n=70) | ||
Age | 33 (23–42) | 22 (8–28) | 37 (23–41) | 71 (59–79) |
Sex (female/male) | 18/11 | 9/10 | 27/24 | 10/16 |
Antibiotic usage | 0 | 2 | 20 | 13 |
Anti-viral drug usage | 0 | 13 | 78 | 22 |
Patients with sputum samples | ||||
Clinical indexes | Healthy controls (N=12, n=15) | Patients (N=142, n=235) | ||
Mild (N=27, n=39) | Moderate (N=89, n=156) | Severe (N=26, n=40) | ||
Age | 32 (25–36) | 23 (18–28) | 38 (24–48) | 62 (47–73) |
Sex (female/male) | 7/5 | 15/12 | 46/43 | 10/16 |
Antibiotic usage | 0 | 4 | 20 | 13 |
Anti-viral drug usage | 0 | 18 | 78 | 22 |
Patients with stool samples | ||||
Clinical indexes | Healthy controls (N=28, n=40) | Patient (N=70, n=112) | ||
Mild (N=22, n=40) | Moderate (N=44, n=68) | Severe (N=4, n=4) | ||
Age | 32 (7–40) | 22 (6–26) | 35 (25–46) | 52 (36–69) |
Sex (female/male) | 15/13 | 12/10 | 19/25 | 1/3 |
Antibiotic usage | 0 | 3 | 8 | 4 |
Anti-viral drug usage | 0 | 17 | 38 | 3 |